Equities research analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX – Get Free Report) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the stock.
Separately, Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, August 16th.
Read Our Latest Stock Report on VolitionRx
VolitionRx Stock Performance
VolitionRx (NYSE:VNRX – Get Free Report) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. On average, analysts predict that VolitionRx will post -0.31 earnings per share for the current year.
Insider Activity
In related news, Director Guy Archibald Innes bought 150,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was bought at an average price of $0.67 per share, with a total value of $100,500.00. Following the purchase, the director now owns 406,683 shares in the company, valued at approximately $272,477.61. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 12.80% of the company’s stock.
VolitionRx Company Profile
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
Featured Stories
- Five stocks we like better than VolitionRx
- What Investors Need to Know to Beat the Market
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Learn Technical Analysis Skills to Master the Stock Market
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Following Congress Stock Trades
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.